THE IBN SINA PHARMACEUTICAL INDUSTRY PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 253.8 BDT | -0.63% |
|
-2.38% | -11.44% |
| Sales 2024 * | 11.18B 102M | Sales 2025 * | 12.74B 116M | Capitalization | 7.93B 72.12M |
|---|---|---|---|---|---|
| Net income 2024 * | 685M 6.23M | Net income 2025 * | 777M 7.07M | EV / Sales 2024 * | 0.71 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.62 x |
| P/E ratio 2024 * |
11.6
x | P/E ratio 2025 * |
10.2
x | Employees | 4,000 |
| Yield 2024 * |
2.68% | Yield 2025 * |
3.03% | Free-Float | 47.44% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.63% | ||
| 1 week | -2.38% | ||
| Current month | -3.57% | ||
| 1 month | -3.31% | ||
| 3 months | -5.40% | ||
| 6 months | -11.44% | ||
| Current year | -11.44% |
1 week
252.30
264.00
1 month
252.30267.90
Current year
252.30286.60
1 year
252.30290.00
3 years
238.00348.00
5 years
192.00348.00
10 years
61.32348.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 69 | 02-12-31 | |
Chowdhury Hasan
DFI | Director of Finance/CFO | 70 | 12-12-31 |
Mohammad Uddin
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 82-12-31 | |
Abdus Bhuiyan
BRD | Director/Board Member | 64 | 22-01-15 |
| Chief Executive Officer | 69 | 02-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 253.8 | -0.63% | 7 106 |
| 24-04-22 | 255.4 | -0.82% | 16,031 |
| 24-04-21 | 257.5 | +1.54% | 13,795 |
| 24-04-18 | 253.6 | -2.12% | 4,562 |
| 24-04-17 | 259.1 | 0.00% | 8,881 |
End-of-day quote Dhaka S.E., April 22, 2024
More quotes
The IBN SINA Pharmaceutical Industry Ltd is a pharmaceutical company in Bangladesh. The Company is engaged in the production of pharmaceutical drugs and natural medicines. It sells its products to both local and international market. The Company offers its products in a range of therapeutic areas, such as anti-allergic occular, anti-arthritis supplement, anti-asthmatic, anti-emetic, antifungal, anti-glucoma, anti-histamine, anti-malarial, anti-protozoal, antibiotic, antivertigo agent, antiviral, cough expectorant, dry eye syndrome, hormone products, nasal decongestant, topical, urinary incontinence and sterois-occular. The Company offers its products under various brand names, such as Aceril, Acipam, Algirex, Azopt, Antigrain, Bactin, Betasil, Buscon, Bromofen, Camide, Cardil, Cloram-D, Cinarzin, Dermacort, Dexon, Donadin, Emiston, Eylon, Fexomin, Fungin, Fruson, Gatsina, Glamor, Hexyclore, Iluca, Inseac, Ketof, Lansina, Lytex, Malex, Metsina, Natazol and Neuralgin.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
253.8
BDT
Average target price
370
BDT
Spread / Average Target
+45.78%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.44% | 72.7M | |
| +17.88% | 44.31B | |
| +19.87% | 22.17B | |
| +13.05% | 14.62B | |
| +8.06% | 13.12B | |
| +39.21% | 11.58B | |
| -8.96% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.50% | 5.03B |
- Stock Market
- Equities
- IBNSINA Stock
